Bright Minds Biosciences Inc (DRUG)
Bright Minds Biosciences Inc. is a biotechnology company listed on the NASDAQ under the ticker DRUG. The company focuses on developing therapeutics intended to address severe and life-altering diseases, with an emphasis on neurological and neuropsychiatric conditions. Its pipeline includes work on 5-HT2 receptor-based programs, including serotonin agonists for epilepsy and neuropsychiatric disorders, as well as BMB-101, which has completed a Phase 1 trial for an undisclosed seizure disorder and is now being evaluated in Phase 2 studies for developmental and epileptic encephalopathies and absence epilepsies. Bright Minds Biosciences is also advancing BMB-201 and BMB-202 for neuropsychiatric and neurology indications, along with BMB-105, a 5-HT2C agonist being developed for Prader-Willi syndrome. The company was founded in 2017 and is headquartered in New York, New York.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DRUG
|
$81.56
|
5.5% Upside
|
Fair
|
$167.11
|
116.1% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
-37.4x
|
3.3x
|
—
|
728.3 M
|
513.4 M
|
0.0%
|
52.2%
|
160.9
|
—
|
72.5%
|
